Analyst Price Target is $33.50
▲ +321.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Pharming Group in the last 3 months. The average price target is $33.50, with a high forecast of $37.00 and a low forecast of $30.00. The average price target represents a 321.38% upside from the last price of $7.95.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Pharming Group.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Read More